Boston Scientific (NYSE:BSX) executive vice president and chief financial officer Jeffrey Capello joined the board of directors at OvaScience, a Boston, Mass.-based start up developing infertility treatments.
Capello began working at Boston Scientific in 2008, landing the CFO seat in 2010. He oversees the company’s global finance, information systems, business development and corporate strategy functions.
"We are very pleased to welcome a seasoned life sciences leader like Jeff to OvaScience’s board of directors, OvaScience co-founder and CEO Dr. Michelle Dipp said in prepared remarks. "Jeff’s financial expertise and perspectives will be invaluable to OvaScience as we continue the development of our novel treatments for infertility."
Capello was thought to be a candidate for the top seat at the Natick, Mass.-based med-tech giant Boston Scientific when former CEO Ray Elliott announced his resignation last year.
Covidien shuffles the deck for vascular therapies
Covidien (NYSE:COV) reorganized management for its vascular therapies business divisions in efforts to "enhance the customer service experience worldwide," the med-tech titan’s new global vascular therapies business head Stacy Enxing Seng announced.
The new organization features 3 divisions: peripheral vascular, neurovascular, and international.
Brian Verrier, a vice president and manager who has lead the venous vascular business unit since October 2010, will head the peripheral vascular division. Neurovascular will be led by Brett Wall, president, who joined the company through the $2.6 billion acquisition of ev3 in the summer of 2010. Chris Hutchinson will lead the international division, having headed European commercial operations of vascular therapies. Read more
Orgenesis names new CEO, CFO, CSO
Orgenesis (OTC:ORGS) announced big changes for its executive team, including the appointments of a new chief executive, chief financial officer and chief science officer.
Jacob BenArie took the corner office at the White Plains, N.Y.-based therapeutic technology maker following 5 years in the top seat at Beta-Stim Ltd, a privately held Type 2 diabetes treatment maker he co-founded.
Dov Weinberg was named CFO, bringing more than 11 years of direct medical device experience. Sarah Ferber, a scientist who has conducted more than a decade diabetes research, became the company’s CSO. Read more
National Standards Authority of Ireland adds 5 to certification committee
The National Standards Authority of Ireland, the agency responsible for management systems and medical device approvals, named 5 members to its independent Certification Oversight Committee.
The new members include Leigh Eichel of Direct Logix, who will serve as chairman, John Rai-Kelly of LTX Corp., Kenneth Melillo of Genzyme Corp. (NSDQ:GENZ), Paul MacMilan of PerkinElmer Inc. (NYSE:PKI) and Ted Cudal of EnviroSafe Systems. Read more
- Cardiologist Dr. Douglas Miller takes over as dean at University of Alberta following ouster of Dr. Philip Baker
- iSonea adds Dr. Ross Macdonald and Dr. Stewart Washer to board of directors, appoints Donal O’Dwyer special advisor
- NeuroSigma appoints Dr. Christopher DeGiorgio VP of neurology
- Hansen Medical names Joseph Guido VP of marketing & business development
- Response Biomedical announces Richard Canote as CFO